Results 71 to 80 of about 12,946 (215)

Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications

open access: yesJournal of Diabetes Investigation, EarlyView.
ABSTRACT Type 1 diabetes is defined by immune‐mediated beta‐cell failure and dependence on exogenous insulin. That definition is correct, but it may not fully describe many people seen in current clinical practice. Overweight and obesity are now common in type 1 diabetes, leading to variable combinations of high insulin requirement, hypertension ...
Zachary Bloomgarden
wiley   +1 more source

In vivo pharmacokinetics of ginsenoside compound K mediated by gut microbiota.

open access: yesPLoS ONE
Ginsenoside Compound K (GCK) is the main metabolite of natural protopanaxadiol ginsenosides with diverse pharmacological effects. Gut microbiota contributes to the biotransformation of GCK, while the effect of gut microbiota on the pharmacokinetics of ...
Ming-Si Deng   +6 more
doaj   +1 more source

Incidence of HNF1A and GCK MODY Variants in a South African Population

open access: yesThe Application of Clinical Genetics, 2020
Tandi E Matsha,1,* Shanel Raghubeer,1,* Abegail M Tshivhase,1 Saarah FG Davids,1 Gloudina M Hon,1 Lise Bjørkhaug,2 Rajiv T Erasmus1 1SAMRC/Cardiometabolic Health Research Unit, Department of Biomedical Sciences, Faculty of Health & Wellness ...
Matsha TE   +6 more
doaj  

The germinal center kinase GCK-1 is a negative regulator of MAP kinase activation and apoptosis in the C. elegans germline. [PDF]

open access: yesPLoS ONE, 2009
The germinal center kinases (GCK) constitute a large, highly conserved family of proteins that has been implicated in a wide variety of cellular processes including cell growth and proliferation, polarity, migration, and stress responses.
Katherine R Schouest   +5 more
doaj   +1 more source

Clinical, Laboratory and Genetic Characteristics of Children with GCK-MODY (MODY2): Report of Four Novel Variants in GCK Gene

open access: yesTrends in Pediatrics, 2020
Objective: Maturity-Onset Diabetes of the Young (MODY) is the most common type of monogenic diabetes. Heterozygous inactivating variants in glucokinase (GCK) gene are related to MODY2 (GCK–MODY). In this study, we aimed to investigate the phenotype and genotype characteristics of patients with GCK–MODY.
Mustafa Altan   +5 more
openaire   +2 more sources

Genetic Landscape and Diagnostic Challenges of MODY: A Comprehensive Review of Etiology, Subtypes, and Future Perspectives

open access: yesHamidiye Medical Journal
Maturity-onset diabetes of the young (MODY) is a monogenic, autosomal-dominant form of diabetes. Because of the phenotypic overlap with other types of diabetes, MODY remains difficult for clinicians to diagnose; many cases are misdiagnosed as type 1 or ...
Şerife Serra Şen   +5 more
doaj   +1 more source

Identification and functional characterisation of novel glucokinase mutations causing maturity-onset diabetes of the young in Slovakia.

open access: yesPLoS ONE, 2012
Heterozygous glucokinase (GCK) mutations cause a subtype of maturity-onset diabetes of the young (GCK-MODY). Over 600 GCK mutations have been reported of which ∼65% are missense.
Lucia Valentínová   +9 more
doaj   +1 more source

Phenomic prediction of club wheat milling yields

open access: yesThe Plant Phenome Journal, Volume 9, Issue 1, December 2026.
Abstract Near‐infrared reflectance spectroscopy (NIRS) provides a nondestructive method for estimating physical and chemical grain properties and is widely used in breeding programs to phenotype traits such as texture, color, moisture, protein, and oil content. Club wheat (Triticum aestivum subsp.
Peter Schmuker   +4 more
wiley   +1 more source

“Pesto” Mutation: Phenotypic and Genotypic Characteristics of Eight GCK/MODY Ligurian Patients

open access: yes, 2023
Maturity Onset Diabetes of the Young (MODY) is a monogenic form of diabetes mellitus (DM) that accounts for around 2–5% of all types of diabetes. Autosomal dominant inheritance in pathogenic variations of 14 genes related to β-cell functions ...
Marina Francesca Strati   +15 more
core   +1 more source

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9633-9643, October 2026.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy